Figure 1.

The in vivo efficacy of MG1 in the B16lacZ tumor model is not dependent on viral oncolysis. (a) B16lacZ cells were in vitro infected with indicated virus at different MOI. Forty-eight hours postinjection, cell viability was assessed by Alamar Blue. (b) B16lacZ cells were injected i.v. into B6 mice via tail vein at day 0. Virus treatment was given at day 1, 3, and 8. At day 14, lung metastases were stained and quantified. (c) Indicated virus treatment was administered at 1 day before B16lacZ tumor cell inoculation. Lung metastases were quantified at 3 days post–tumor injection. Data are representative of three similar experiments with n = 5–6/group (*P < 0.05; ***P < 0.001; ns, not significant).